In a very meta-Assessment of 6 randomized controlled trials that enrolled hospitalized sufferers with COVID-19, the usage of non-SARS-CoV-two-unique IVIG wasn't affiliated with a survival profit.1 Each of the incorporated trials had been conducted in 2020, once the presence of SARS-CoV-two antibodies in blood donors was most likely unheard of. Not